# Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

> **NCT01190410** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 16 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** certolizumab pegol
- **DRUG:** certolizumab pegol

## Key facts

- **NCT ID:** NCT01190410
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2017-11-27
- **Final completion:** 2017-11-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01190410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01190410, "Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01190410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*